Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  Advanced Cell Technology, Inc.    ACTC

SummaryNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Advanced Cell Technology : Announces 1:100 Reverse Stock Split

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/27/2014 | 11:13pm CEST

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced that it has completed a 1:100 reverse split of its common stock.

“Completing this reverse stock split is an important step in our plan to improve our corporate structure and establish ACT as a highly-regarded, publicly-traded biotechnology company. With continued progress in many of our clinical and pre-clinical programs, the Lincoln Park equity facility in place and Dr. Wotton’s arrival as CEO, this initiative is part of a larger strategy to up-list to a national stock exchange and to raise awareness and visibility with fundamental-based, institutional biotech investors,” said Ted Myles, ACT’s Chief Financial Officer and Chief Operating Officer.

As a result of the reverse stock split, every 100 shares of the Company’s pre-reverse stock split common stock were combined and reclassified into one share of the Company’s common stock. Beginning with the opening of trading on August 28, 2014, the Company’s common stock will trade on the OTC Markets Group on a reverse stock split adjusted basis.

More information is available in ACT's Current Report on Form 8-K, filed today with the SEC.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., (ACT) is a clinical stage biotechnology company focused on the development and commercialization of regenerative medicine and cell therapy technology. The company’s most advanced products are in clinical trials for the treatment of dry age-related macular degeneration, Stargardt’s macular degeneration and myopic macular degeneration. ACT’s preclinical programs involve cell therapies for the treatment of other ocular disorders and for diseases outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders. The company’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs. For more information, visit www.advancedcell.com

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the Company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the Company’s periodic reports, including our report on Form 10-K for the year ended December 31, 2013 and our report on Form 10-Q for the three and six months ended June 30, 2014. Forward-looking statements are based on the beliefs, opinions, and expectations of the Company’s management at the time they are made, and the Company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the Company’s management at the time they are made, and the Company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials or other development programs will be successful.


© Business Wire 2014
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ADVANCED CELL TECHNOLOGY,
02/18 ASTELLAS PHARMA : Announces Results of Tender Offer to Acquire All Outstanding S..
02/10 OCATA THERAPEUTICS : Astellas Announces Results of Tender Offer to Acquire All O..
02/09 OCATA THERAPEUTICS INC : Ocata Therapeutics, Inc. (NASDAQ: OCAT) Acquisition; Te..
01/27 ASTELLAS PHARMA : Extends Tender Offer to Acquire All Outstanding Shares of Ocat..
01/25 ASTELLAS PHARMA : Extends Tender Offer to Acquire All Outstanding Shares of Ocat..
01/22 OCATA THERAPEUTICS : Astellas Extends Tender Offer to Acquire All Outstanding Sh..
2015 OCATA THERAPEUTICS : Reports the Publication of Data about the Generation of Cor..
2015 OCATA THERAPEUTICS : Entry into a Material Definitive Agreement, Financial State..
2015 OCATA THERAPEUTICS : Patent Issued for Modalities for the Treatment of Degenerat..
2015 OCATA THERAPEUTICS : Hemangio-derived Mesenchymal Cells Preserve Kidney Function..
More news
Sector news : Bio Therapeutic Drugs
09/29DJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
Advertisement
Managers
NameTitle
Masao Yoshida President, Chief Executive Officer & Director
Shi-Jiang Lu Senior Director-Research
Linda Friedman Secretary & Director
Stephen Knowles Treasurer & Director
Rita Parker Operations Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ADVANCED CELL TECHNOLO..0
AMGEN, INC.1.92%123 816
GILEAD SCIENCES, INC.-23.06%102 749
CELGENE CORPORATION-14.19%79 659
REGENERON PHARMACEUTIC..-25.15%42 787
VERTEX PHARMACEUTICALS..-32.45%21 061
More Results